Cinoxacin: new antimicrobial agent for urinary tract infections

Area of Science:

• Pharmacology
• Infectious Diseases
• Urology

Background:

• Recurrent urinary tract infections (UTIs) pose a significant clinical challenge.
• Bacteriuria, particularly with high bacterial counts, is a hallmark of UTIs.
• Assessing treatment efficacy and resistance patterns is crucial for managing UTIs.

Purpose of the Study:

• To evaluate the efficacy and safety of cinoxacin in treating recurrent urinary tract infections.
• To assess the clinical response in patients with and without complicating factors.
• To investigate pathogen eradication, recurrence rates, and emergence of resistance.

Main Methods:

• A clinical study involving 146 patients with recurrent UTIs.
• Treatment with cinoxacin 500 mg twice daily for 7-14 days.
• Analysis of clinical response, bacteriuria, pathogen elimination, resistance, and adverse effects.

Main Results:

• A 94% satisfactory clinical response rate was observed.
• Patients without complicating conditions showed higher pathogen elimination (90% vs 80%) and lower recurrence (3% vs 14%).
• Adverse effects were minimal (2.7%), and resistance emerged in 5% of patients.

Conclusions:

• Cinoxacin demonstrates high efficacy and a favorable safety profile for recurrent UTIs.
• Treatment outcomes are influenced by the presence of complicating factors.
• Further investigation into cinoxacin disk diffusion susceptibility testing is warranted.